BRIEF-Bluebird Bio Inc initiates expansion cohort of CRB-401 Phase 1 study of bb2121
September 13, 2017 at 08:13 AM EDT
* bluebird bio Inc - expansion cohort of crb-401 phase 1 study of bb2121, an anti-BCMA CAR T therapy, has been initiated